Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New transplant method shows promise for tough blood cancers

NCT ID NCT02623439

Disease control Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a bone marrow transplant using a partially matched family donor for people with blood cancers like leukemia. The goal was to see if a milder conditioning regimen and a drug called cyclophosphamide could help patients survive at least 180 days after transplant. The study was stopped early, but the approach aims to make transplants safer and available to more patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

10 people

The number who actually took part.

Started

Sep 2012

Finished

Jan 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age: Subjects 18-70 years old. 2. Donor must be 18 years of age. 3. HLA typing will be performed at high resolution. A minimum match of 5 out of 10 is required. 4. Patients must have received multi-agent chemotherapy within 3 months of consent date (measured from the start date of chemotherapy). 5. Acute Leukemias. * Acute Lymphoblastic Leukemia in high risk 1st complete response (CR1) * Acute Myelogenous Leukemia in high risk 1st complete response (CR1) * Acute Leukemias in 2nd or subsequent Complete Response (CR) * Biphenotypic/Undifferentiated Leukemias in 1st or subsequent Complete Response (CR). 6. Burkitt's lymphoma: second or subsequent Complete Response (CR). 7. Lymphoma 8. Patients with adequate physical function 9. Performance status: Karnofsky score 70-100%. Exclusion Criteria:

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute lymphoblastic leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute biphenotypic leukemia acute lymphoblastic leukemia acute myeloid leukemia acute undifferentiated leukemia Burkitt lymphoma CD4+/CD56+ hematodermic neoplasm follicular lymphoma hematopoietic and lymphoid system neoplasm Hodgkins lymphoma large B-cell lymphoma marginal zone lymphoma myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematologic malignancies

Contacts and locations

Locations

  • UCSD Medical Center

    La Jolla, California, 92093, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.